97. 潰瘍性大腸炎
[臨床試験数:2,269,薬物数:1,331(DrugBank:241),標的遺伝子数:114,標的パスウェイ数:181

Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2011-001568-22-HU
(EUCTR)
15/01/201318/07/2012A placebo-controlled trial with rFXIII administered to subjects with mild to moderate active ulcerative colitisA multicenter, randomised, double-blind, placebo-controlled, multiple-dose trial with rFXIII administered to subjects with mild to moderate active ulcerative colitis Mild to moderate Ulcerative Colitis
MedDRA version: 14.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Recombinant Factor XIII (rFXIII)
INN or Proposed INN: Catridecacog
Novo Nordisk A/SNULLNot RecruitingFemale: yes
Male: yes
90Hungary;European Union;Ukraine;Croatia;Denmark;Bulgaria;Russian Federation
2EUCTR2011-001568-22-BG
(EUCTR)
05/10/201216/08/2012A placebo-controlled trial with rFXIII administered to subjects with mild to moderate active ulcerative colitisA multicenter, randomised, double-blind, placebo-controlled, multiple-dose trial with rFXIII administered to subjects with mild to moderate active ulcerative colitis Mild to moderate Ulcerative Colitis
MedDRA version: 16.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Recombinant Factor XIII (rFXIII)
INN or Proposed INN: Catridecacog
Novo Nordisk A/SNULLNot RecruitingFemale: yes
Male: yes
90Hungary;European Union;Ukraine;Croatia;Denmark;Russian Federation;Bulgaria
3NCT01706159
(ClinicalTrials.gov)
October 20129/10/2012A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative ColitisA Multicenter, Randomised, Double-blind, Placebo-controlled, Multiple-dose Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative ColitisInflammation;Ulcerative ColitisDrug: catridecacog;Drug: placeboNovo Nordisk A/SNULLTerminated18 Years64 YearsAll20Phase 2Bulgaria;Croatia;Denmark;Hungary;Poland;Russian Federation;Ukraine
4EUCTR2011-001568-22-DK
(EUCTR)
23/08/201202/08/2012A placebo-controlled trial with rFXIII administered to subjects with mild to moderate active ulcerative colitisA multicenter, randomised, double-blind, placebo-controlled, multiple-dose trial with rFXIII administered to subjects with mild to moderate active ulcerative colitis Mild to moderate Ulcerative Colitis
MedDRA version: 14.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Recombinant Factor XIII (rFXIII)
INN or Proposed INN: Catridecacog
Novo Nordisk A/SNULLNot RecruitingFemale: yes
Male: yes
90Hungary;European Union;Ukraine;Croatia;Denmark;Bulgaria;Russian Federation